MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Medica Scientia Innovation Research (MEDSIR)MEDSIR announced today the positive results of the PHERGain trial. This study is the first to use an adaptive design that tailors treatment in the neoadjuvant/adjuvant setting of patients with HER2-positive early breast cancer. The main objective of this trial was to assess the feasibility of a chemotherapy-free strategy based on a dual HER2 blockade with trastuzumab and pertuzumab through a positron emission tomography (PET)-based, pathologic complete response response(pCR)-adapted strategy.